Jean L. Koff, MD, MS

home / authors / jean-l-koff-md-ms

Articles

Jean L. Koff, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute

Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL

Jean L. Koff, MD, MS
September 27th 2024

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

Read More

Jean L. Koff, MD, MS

Dr Koff on the Role of Covalent BTK Inhibitors and Pirtobrutinib in MCL

Jean L. Koff, MD, MS
September 5th 2024

Jean L. Koff, MD, MS, discusses the role of covalent BTK inhibitors in the treatment of mantle cell lymphoma.

Read More

Jean L. Koff, MD, MS

Dr Koff on BTK Inhibitors vs Venetoclax-Based Regimens in First-Line CLL

Jean L. Koff, MD, MS
August 23rd 2024

Jean L. Koff, MD, MS, discusses considerations around using BTK inhibitors vs venetoclax-based regimens in first-line chronic lymphocytic leukemia.

Read More

Jean L. Koff, MD, MS

Dr Koff on Toxicities Associated With Pirtobrutinib in MCL

Jean L. Koff, MD, MS
May 15th 2024

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

Read More

Jean L. Koff, MD, MS

Dr Koff on the Safety Profile of Pirtobrutinib in Pretreated CLL/SLL

Jean L. Koff, MD, MS
May 14th 2024

Jean L. Koff, MD, MS, discusses the safety profile of pirtobrutinib in pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Read More

Dr. Koff on Systemic Therapy Options in Follicular Lymphoma

Dr. Koff on Systemic Therapy Options in Follicular Lymphoma

Jean L. Koff, MD, MS
January 17th 2020

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC